



ASX / MEDIA RELEASE

Investor Conference Call

Brisbane, Australia, 12 April 2018 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, will host a conference call on **Monday 16 April at 11am AEST** to discuss the preliminary results from its proof-of-concept obstructive sleep apnoea clinical study. Tony Keating, Managing Director and CEO, will host the call.

Conference Call Details:

Date: Monday 16 April, 11am AEST

Conference ID: 2658 229

Access:

- Australia: +61 2 8038 5221
- New Zealand: 0800 452 782
- China: 4001 203 085
- Hong Kong: 800 908 865
- Singapore: 800 616 2288
- United Kingdom: 0808 234 0757
- United States: 1855 293 1544

Participants will need to provide their name and to ask a question, they will need to dial “*1” (star, 1) on their telephone keypad.

A recording will be available four hours after the end of the call on openbriefing.com.

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. ResApp has adult and paediatric clinical studies underway at leading hospitals in the United States and Australia with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a proof-of-concept clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 **E** info@resapphealth.com.au **W** www.resapphealth.com.au



Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 **E** info@resapphealth.com.au **W** www.resapphealth.com.au